OraSure Technologies Q2 Earnings Call Highlights

OraSure Technologies Q2 revenue rose 9.7% sequentially to $30.6 million , exceeding guidance, as diagnostic-products revenue increased 14.7% and sample-management revenue grew 9%. Stronger public-health demand, syphilis testing, Sickle SCAN and laboratory recovery supported the results. OraSure achieved key regulatory milestones with FDA clearance for its Colli-Pee Dx STI urine-collection kit and Emergency Use Authorization for the OraQuick Ebola 2.0 test. However, the company delayed its expected 2026 U.S. launch of the IntelliQuick CT/NG test and plans to revise and resubmit its application. Gross margin improved to 43.5%, while the company ended the quarter debt-free with $161 million in cash. Management expects third-quarter revenue of $29.5 million to $32.5 million and continues targeting operating cash-flow break-even as it enters 2027. OraSure Technologies NASDAQ: OSUR reported second-quarter revenue of $30.6 million, exceeding its guidance range and rising 9.7% sequentially, as stronger public-health diagnostics demand and growth in sample-management products supported results. President and Chief Executive Officer Carrie Eglinton Manner said the quarter marked continued progress in the company’s transformation, citing sequential gross-margin improvement, new regulatory milestones and efforts to position the business for growth in the second half of 2026 and beyond. “Q2 demonstrated that transition beginning to take shape through stronger revenue, improving margins, and meaningful innovation milestones,” Eglinton Manner said. Diagnostics and Sample Management Growth Diagnostic-products revenue totaled $19.4 million, increasing 14.7% from the prior quarter. Chief Financial Officer Ken McGrath said U.S. diagnostics revenue exceeded international revenue during the period. The sequential gain reflected stronger public-health demand, including customer purchasing associated with fiscal-year cycles, higher syphilis-test revenue and contributions from BioMedomics’ Sickle SCAN product. The company said demand for its OraQuick HIV Self-Test was strong in U.S. public-health programs despite ongoing federal funding pressure. OraSure also cited growth in consumer and business-to-business-to-consumer channels, including telehealth and digital-access outlets. Internationally, OraSure said it is seeking to diversify and localize its diagnostics business. The company continues to support long-standing HIV testing customers while pursuing nearshoring and in-country value-added assembly programs for OraQuick HIV Self-Test products. Eglinton Manner said the company expects to provide additional details on localization initiatives later this year. Sickle SCAN revenue is growing at twice the rate in 2026 as it did in 2025, according to Eglinton Manner, as OraSure integrates the product into its international commercial channels and pursues national health-program opportunities. Sample Management Solutions revenue was $9.9 million, up 9% sequentially, with growth across segments. OraSure said it saw improving demand among commercial and advanced diagnostic-testing laboratories, microbiome-collection applications and early signs of recovery in academic and research markets. During the question-and-answer session, Eglinton Manner said the company is seeing a “fairly consistent recovery” among advanced genetic-testing laboratories, while noting that the segment has remained muted since the COVID period. Regulatory Milestones and IntelliQuick Delay In June, OraSure received FDA clearance for its Colli-Pee Dx urine collection kit, which enables at-home self-collection of volumetric first-void ur...